Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | NOS3 | P29474 | 5/20 | 0.47 |
| ▸ | NOS1 | P29475 | 5/20 | 0.47 |
| ▸ | NOS2 | P35228 | 5/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | ALPI | P09923 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | XIAP | P98170 | 1/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.46 |
| ▸ | MPO | P05164 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | RECQL | P46063 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28879239 | 1.00 | KMT2A (0.55) | KMT2AMEN1NOS3NOS1NOS2 | |
| SCHEMBL1072482 | 1.00 | KMT2A (0.55) | KMT2AMEN1NOS3NOS1NOS2 | |
| SCHEMBL5527768 | 0.81 | KMT2A (0.55) | KMT2AMEN1KDM4EMAPTTSHR | |
| SCHEMBL29482763 | 0.79 | CTNNB1 (0.59) | KMT2AMEN1NOS3NOS1NOS2 | |
| SCHEMBL93515 | 0.79 | CTNNB1 (0.59) | KMT2AMEN1NOS3NOS1NOS2 | |
| SCHEMBL660499 | 0.79 | CTNNB1 (0.59) | KMT2AMEN1NOS3NOS1NOS2 | |
| SCHEMBL29397858 | 0.79 | CTNNB1 (0.59) | KMT2AMEN1NOS3NOS1NOS2 | |
| SCHEMBL93516 | 0.79 | CTNNB1 (0.59) | KMT2AMEN1NOS3NOS1NOS2 | |
| SCHEMBL29397866 | 0.79 | CTNNB1 (0.59) | KMT2AMEN1NOS3NOS1NOS2 | |
| Pyrene SCHEMBL28205462 | 0.79 | SLC7A5 (0.76) | NOS3NOS1NOS2PKMALPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12616761-B2 | CXCR4-targeting compounds | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2026-05-05 | — | — | US | disclosed |
| US-20260077073-A1 | GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR)-TARGETED COMPOUNDS AND USES THEREOF | ALPHA 9 ONCOLOGY INC (CA) | 2026-03-19 | — | — | US | disclosed |
| US-12514939-B2 | Stable radiopharmaceutical compositions and uses thereof | ALPHA-9 ONCOLOGY, INC. (CA) | 2026-01-06 | — | — | US | disclosed |
| US-12472272-B2 | Radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen- expressing cancer | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2025-11-18 | — | — | US | disclosed |
| US-12427209-B2 | Dual mode 18F-labelled theranostic compounds and uses thereof | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2025-09-30 | — | — | US | disclosed |
| US-20250255993-A1 | STABLE RADIOPHARMACEUTICAL COMPOSITIONS AND USES THEREOF | ALPHA-9 ONCOLOGY INC. (CA) | 2025-08-14 | — | — | US | disclosed |
| US-20250242064-A1 | CXCR4-TARGETING COMPOUNDS, AND METHODS OF MAKING AND USING THE SAME | ALPHA-9 ONCOLOGY INC. (CA) | 2025-07-31 | — | — | US | disclosed |
| US-20250195702-A1 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2025-06-19 | — | — | US | disclosed |
| US-20250186627-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2025-06-12 | — | — | US | disclosed |
| CN-120081907-A | Radiolabeled bombesin derivative compounds for in vivo imaging of the Gastrin Releasing Peptide Receptor (GRPR) and treatment of GRPR-related disorders | 省卫生服务机构 | 2025-06-03 | — | — | CN | disclosed |
| US-20210402016-A1 | RADIOLABELED BOMBESIN-DERIVED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2021-12-30 | — | — | US | disclosed |
| US-20210338851-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2021-11-04 | — | — | US | disclosed |
| EP-3897751-A1 | <SUP2/>? <SUB2/>?18? ?DUAL MODEF-LABELLED THERANOSTIC COMPOUNDS AND USES THEREOF | Provincial Health Services Authority (CA) | 2021-10-27 | — | — | EP | disclosed |
| CN-113454098-A | Radiolabeled bombesin derivative compounds for in vivo imaging of Gastrin Releasing Peptide Receptor (GRPR) and treatment of GRPR related disorders | 省卫生服务机构 | 2021-09-28 | — | — | CN | disclosed |
| EP-3880691-A1 | RADIOLABELED BOMBESIN-DERIVED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | Provincial Health Services Authority (CA) | 2021-09-22 | — | — | EP | disclosed |
| WO-2021068051-A1 | RADIOLABELED BOMBESIN-DERIVED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2021-04-15 | — | — | WO | disclosed |
| WO-2020252598-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020210919-A1 | NOVEL RADIOLABELLED CXCR4-TARGETING COMPOUNDS FOR DIAGNOSIS AND THERAPY | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2020-10-22 | — | — | WO | disclosed |
| WO-2020210909-A1 | NOVEL RADIOLABELLED COMPOUNDS FOR DIAGNOSIS OR TREATMENT OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN-EXPRESSING CANCER | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2020-10-22 | — | — | WO | disclosed |
| WO-2020124237-A1 | DUAL MODE 18F-LABELLED THERANOSTIC COMPOUNDS AND USES THEREOF | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250242064-A1 | CXCR4-TARGETING COMPOUNDS, AND METHODS OF MAKING AND USING THE SAME | CXCR4, CXCL12, ACKR3 | KMT2A 4385/4885MEN1 2317/4885NOS3 3411/4885 |
| US-20210338851-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | FOLH1, KLK3, PSMA3 | KMT2A 1402/4885MEN1 75/4885NOS3 1755/4885 |
| US-20250186627-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | FSHR, ESRRA, ESRRG | KMT2A 3795/4885MEN1 1094/4885NOS3 4479/4885 |
| US-12427209-B2 | Dual mode 18F-labelled theranostic compounds and uses thereof | TFRC, SLC39A3, SLC39A14 | KMT2A 2434/4885MEN1 79/4885NOS3 4384/4885 |
| US-20250255993-A1 | STABLE RADIOPHARMACEUTICAL COMPOSITIONS AND USES THEREOF | RCN1, RABL6, QPCT | KMT2A 3065/4885MEN1 193/4885NOS3 4202/4885 |
| US-12616761-B2 | CXCR4-targeting compounds | CXCR4, CXCR2, CXCR3 | KMT2A 3174/4885MEN1 3462/4885NOS3 2987/4885 |
| US-12472272-B2 | Radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen- expressing cancer | KLK3, FOLH1, HRH3 | KMT2A 484/4885MEN1 423/4885NOS3 2689/4885 |
| US-20210402016-A1 | RADIOLABELED BOMBESIN-DERIVED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | GRPR, NPY1R, GIPR | KMT2A 3383/4885MEN1 943/4885NOS3 1559/4885 |
| US-20250195702-A1 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | GRPR, NPY5R, NPY2R | KMT2A 1870/4885MEN1 708/4885NOS3 4059/4885 |
| US-20260077073-A1 | GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR)-TARGETED COMPOUNDS AND USES THEREOF | GRPR, GIPR, GLP1R | KMT2A 4091/4885MEN1 901/4885NOS3 4003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.